CLOs on the Move

Avita Medical

www.avitamedical.com

 
Avita Medical is a publicly listed regenerative medicine company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). The company`s lead product, ReCell® is used in a wide variety of burns, chronic wounds, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA- registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Brett Silton
Head of Corporate Compliance Profile
Donna Shiroma
General Counsel Profile

Similar Companies

Nucletron

Nucletron Corp. is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ConvaTec

ConvaTec is a global medical products and technologies company with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. Our brands include AQUACEL® advanced wound dressings, which form a gel on contact with wound fluid, creating an optimal environment for wound healing. ConvaTec has more than 9,000 employees with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. We are owned by Nordic Capital and Avista Capital Partners.

Dentamach

Dentamach Incorporated is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

centennial medical group

centennial medical group is a Ellicott City, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HeartFlow

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow`s footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care.